{"id":"hydrochlorothiazide-hctz","safety":{"commonSideEffects":[{"rate":"10-20","effect":"Hypokalemia"},{"rate":"5-10","effect":"Hyperglycemia"},{"rate":"5-10","effect":"Hyperuricemia"},{"rate":"1-5","effect":"Hyponatremia"},{"rate":"5-15","effect":"Hypotension"},{"rate":"5-10","effect":"Dizziness"},{"rate":"5-10","effect":"Headache"},{"rate":"1-5","effect":"Photosensitivity"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"HCTZ is a thiazide diuretic that blocks the sodium-chloride cotransporter (NCC) in the distal convoluted tubule, preventing reabsorption of sodium and chloride. This increases urinary sodium and water excretion, leading to decreased blood volume and reduced peripheral vascular resistance. The resulting decrease in blood pressure makes it effective for hypertension management, and it is often used as a first-line antihypertensive agent.","oneSentence":"Hydrochlorothiazide inhibits sodium and chloride reabsorption in the distal convoluted tubule of the kidney, promoting water and electrolyte excretion to reduce blood volume and blood pressure.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:32:12.656Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"},{"name":"Edema associated with congestive heart failure"},{"name":"Edema associated with renal disease"}]},"trialDetails":[{"nctId":"NCT07469722","phase":"PHASE2, PHASE3","title":"POcus INTERvention for Tailoring Diuretic Strategy in Acute Decompensated Heart Failure","status":"NOT_YET_RECRUITING","sponsor":"Hospital de Clinicas de Porto Alegre","startDate":"2026-03-23","conditions":"Acute Heart Failure (AHF), Congestive Heart Failure Acute, Diuretic Effect","enrollment":128},{"nctId":"NCT07458880","phase":"NA","title":"Triple Antihypertensive Medication After Intracerebral Hemorrhage for Blood Pressure Control","status":"RECRUITING","sponsor":"The University of Hong Kong","startDate":"2026-03-01","conditions":"Intracerebral Hemorrhage","enrollment":140},{"nctId":"NCT05373264","phase":"PHASE3","title":"HYDROchlorothiazide to PROTECT Polycystic Kidney Disease Patients and Improve Their Quality of Life","status":"RECRUITING","sponsor":"University Medical Center Groningen","startDate":"2024-07-31","conditions":"ADPKD","enrollment":300},{"nctId":"NCT06041529","phase":"PHASE4","title":"Study to Evaluate the Efficacy and Safety of TEL/AML/CTD in Elderly Patients With Essential Hypertension","status":"ACTIVE_NOT_RECRUITING","sponsor":"Yuhan Corporation","startDate":"2023-10-18","conditions":"Essential Hypertension","enrollment":198},{"nctId":"NCT03511118","phase":"","title":"Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants","status":"RECRUITING","sponsor":"Duke University","startDate":"2018-10-04","conditions":"Lactating Women on Select DOI, Breastfed Infants of Mothers on Select DOI","enrollment":1600},{"nctId":"NCT03892148","phase":"PHASE4","title":"Protocol of Diuretics Use in Congestive Therapy in Heart Failure","status":"COMPLETED","sponsor":"University Hospital, Clermont-Ferrand","startDate":"2019-05-17","conditions":"Heart Failure, Acute Heart Failure, Chronic Heart Failure","enrollment":299},{"nctId":"NCT05609513","phase":"NA","title":"Integration of Hypertension Management in HIV Care in Uganda","status":"COMPLETED","sponsor":"Infectious Diseases Research Collaboration, Uganda","startDate":"2023-02-06","conditions":"HIV/AIDS, Hypertension","enrollment":87421},{"nctId":"NCT05171686","phase":"PHASE4","title":"Diuretics and Volume Overload in Early CKD","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2023-02-01","conditions":"Chronic Kidney Disease, Hypertension","enrollment":49},{"nctId":"NCT07271420","phase":"PHASE4","title":"Blood Pressure Control With Thiazide Diuretics in Peritoneal Dialysis Patients","status":"RECRUITING","sponsor":"Chinese University of Hong Kong","startDate":"2020-01-01","conditions":"Hypertension, Peritoneal Dialysis, End Stage Kidney Disease (ESRD)","enrollment":40},{"nctId":"NCT02483936","phase":"PHASE3","title":"Efficacy and Safety of Olmesartan Associated With Chlorthalidone Versus Benicar HCT® in Essential Hypertension Control","status":"WITHDRAWN","sponsor":"EMS","startDate":"","conditions":"Arterial Hypertension","enrollment":""},{"nctId":"NCT02493322","phase":"PHASE3","title":"Efficacy and Safety of Olmesartan Associated With Chlorthalidone in Essential Arterial Hypertension Control","status":"WITHDRAWN","sponsor":"EMS","startDate":"","conditions":"Essential Arterial Hypertension","enrollment":""},{"nctId":"NCT05963568","phase":"PHASE3","title":"Stroke Minimization Through Additive Anti-atherosclerotic Agents in Routine Treatment II Study (SMAART II)","status":"NOT_YET_RECRUITING","sponsor":"Northern California Institute of Research and Education","startDate":"2026-01-01","conditions":"Stroke, Medication Adherence","enrollment":680},{"nctId":"NCT05049616","phase":"PHASE4","title":"Oral Combined Hydrochlorothiazide/Lisinopril Versus Oral Nifedipine for Postpartum Hypertension","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2021-10-18","conditions":"Hypertension in Pregnancy, Postpartum Preeclampsia","enrollment":70},{"nctId":"NCT05125224","phase":"","title":"Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Dihydropyridine Calcium Channel Blockers Versus Hydrochlorothiazide","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2021-10-01","conditions":"Hypertension","enrollment":163720},{"nctId":"NCT05413057","phase":"","title":"An OS to Evaluate Effectiveness and Safety of Fixed-dose Combinations of FMS/AML or FMS/AML/HCTZ","status":"RECRUITING","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2022-06-23","conditions":"Hypertension,Essential","enrollment":20000},{"nctId":"NCT04676399","phase":"EARLY_PHASE1","title":"Improving Pain Management Via Spinal Cord Stimulation and Blood Pressure Reduction","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Kansas Medical Center","startDate":"2022-02-08","conditions":"Chronic Pain, Hypertension, Diuretics Drug Reactions","enrollment":36},{"nctId":"NCT04654312","phase":"PHASE1","title":"Study to Evaluate the Influence of Hydrochlorothiazide on Dermal Photosensitivity and DNA Stability - a Pilot Study (HCTox Study)","status":"COMPLETED","sponsor":"Universität des Saarlandes","startDate":"2021-01-18","conditions":"Photosensitivity","enrollment":30},{"nctId":"NCT04423627","phase":"EARLY_PHASE1","title":"Sympathetic Regulation of Large Artery Stiffness in Humans With ISH","status":"COMPLETED","sponsor":"University of Iowa","startDate":"2021-06-01","conditions":"Hypertension, Systolic, Stiffness, Aortic","enrollment":100},{"nctId":"NCT06841692","phase":"NA","title":"Diuretic Testing in Chronic Kidney Disease","status":"RECRUITING","sponsor":"Erasmus Medical Center","startDate":"2025-04-01","conditions":"Kidney Disease, Chronic","enrollment":86},{"nctId":"NCT02373163","phase":"PHASE4","title":"INTERVENCION Trial","status":"COMPLETED","sponsor":"Prevencion","startDate":"2014-09-01","conditions":"Blood Pressure, High","enrollment":166},{"nctId":"NCT03295734","phase":"PHASE2","title":"ACES - ACE Inhibitors Combined With Exercise for Seniors With Hypertension","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2018-05-29","conditions":"Hypertension, Aging, Sedentary Lifestyle","enrollment":223},{"nctId":"NCT05920005","phase":"PHASE3","title":"Candesartan Cilexetil + Chlorthalidone + Amlodipine Versus Exforge HCT®️ for Systemic Arterial Hypertension","status":"COMPLETED","sponsor":"Hospital Israelita Albert Einstein","startDate":"2023-08-22","conditions":"Hypertension","enrollment":702},{"nctId":"NCT03553810","phase":"PHASE2","title":"Role of ARNi in Ventricular Remodeling in Hypertensive LVH","status":"COMPLETED","sponsor":"National Heart Centre Singapore","startDate":"2019-04-12","conditions":"Hypertensive Heart Disease","enrollment":80},{"nctId":"NCT07020104","phase":"NA","title":"The Role of Skin Sodium Accumulation in Chronic Kidney Disease","status":"RECRUITING","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2025-01-07","conditions":"Chronic Kidney Diseases","enrollment":60},{"nctId":"NCT07008365","phase":"PHASE3","title":"The Role of intraABDOminal Pressure and Point Of Care UltraSound to Guide Decongestive Therapy in Heart Failure","status":"RECRUITING","sponsor":"Instituto de Investigación Sanitaria Aragón","startDate":"2025-03-10","conditions":"Acute Heart Failure, Congestive Heart Failure, Intraabdominal Hypertension","enrollment":168},{"nctId":"NCT03476551","phase":"","title":"Bariatric Surgery and Pharmacokinetics of Hydrochlorothiazide","status":"RECRUITING","sponsor":"Norwegian University of Science and Technology","startDate":"2016-11-02","conditions":"Obesity, Morbid","enrollment":12},{"nctId":"NCT04934228","phase":"PHASE1","title":"Mitigating the Pro-inflammatory Phenotype of Obesity","status":"RECRUITING","sponsor":"University of Kansas Medical Center","startDate":"2021-07-01","conditions":"Blood Pressure, Diabetes, Obesity","enrollment":60},{"nctId":"NCT03946514","phase":"PHASE4","title":"Efficacy and Safety of a Single-pill Fixed Combination of Sufficient Losartan/Hydrochlorothiazide in Chinese Hypertensive Patients","status":"COMPLETED","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2018-09-01","conditions":"Hypertension","enrollment":180},{"nctId":"NCT06205407","phase":"PHASE1","title":"A Study to Learn How the Body Processes Spironolactone and Hydrochlorothiazide Film Coated Tablets Manufactured at Two Sites: Viatris and Neolpharma","status":"COMPLETED","sponsor":"Pfizer","startDate":"2023-12-26","conditions":"Healthy Participants","enrollment":42},{"nctId":"NCT04927299","phase":"PHASE3","title":"Efficacy and Safety of Losartan/Chlorthalidone vs Losartan/Hydrochlorothiazide in Essential Arterial Hypertension","status":"COMPLETED","sponsor":"Laboratorios Silanes S.A. de C.V.","startDate":"2022-06-30","conditions":"Essential Arterial Hypertension","enrollment":163},{"nctId":"NCT06362668","phase":"NA","title":"EU Sites: Fluid Management of Acute Decompensated Heart Failure With Reprieve Decongestion Management System (FASTR-EU)","status":"COMPLETED","sponsor":"Reprieve Cardiovascular, Inc","startDate":"2024-05-17","conditions":"Acute Decompensated Heart Failure","enrollment":12},{"nctId":"NCT06111885","phase":"PHASE2","title":"Indapamide and Chlorthalidone to Reduce Urine Supersaturation for Kidney Stone Prevention","status":"RECRUITING","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2024-10-01","conditions":"Kidney Stone","enrollment":99},{"nctId":"NCT06790927","phase":"NA","title":"Standardized Antihypertensive Treatment Protocol","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2025-02-24","conditions":"Hypertension","enrollment":400},{"nctId":"NCT06377449","phase":"NA","title":"Influence of Lung Ultrasonography on the Prognosis and Postoperative Outcomes in Cardiac Surgical Patients","status":"RECRUITING","sponsor":"Saint Petersburg State University, Russia","startDate":"2024-05-15","conditions":"Ischemic Heart Disease, Aortic Stenosis, Severe, Aortic Insufficiency","enrollment":186},{"nctId":"NCT06710600","phase":"NA","title":"Phototoxicity of Frequently Prescribed Medicines","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2022-09-22","conditions":"Phototoxicity","enrollment":12},{"nctId":"NCT06681116","phase":"NA","title":"Use of Nanotechnology Structured Water for the Prevention of Recurrent Stone Formation","status":"COMPLETED","sponsor":"ALI KAMAL M. SAMI","startDate":"2015-02-16","conditions":"Renal Stones, Idiopathic Hypercalciuria","enrollment":325},{"nctId":"NCT00690521","phase":"NA","title":"A Comparison of Hydrochlorothiazide and Metolazone in Combination With Furosemide in Congestive Heart Failure Patients","status":"COMPLETED","sponsor":"University of New Mexico","startDate":"2004-10-26","conditions":"Congestive Heart Failure","enrollment":8},{"nctId":"NCT05897372","phase":"PHASE2","title":"Feasibility of Aggressive Albuminuria Reduction in Biopsy-Proven Diabetic Nephropathy - a Pilot Study","status":"TERMINATED","sponsor":"Iain Bressendorff","startDate":"2023-08-01","conditions":"Diabetic Kidney Disease","enrollment":1},{"nctId":"NCT04334824","phase":"","title":"Hydrochlorothiazide and Risk of Skin Cancer","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2019-05-27","conditions":"Non-melanoma Skin Cancer, Melanoma, Hypertension","enrollment":2953748},{"nctId":"NCT01149473","phase":"PHASE1","title":"Losartan Potassium/Hydrochlorothiazide 100/25 mg Tablets in Healthy Subjects Under Non-Fasting Conditions","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2004-03","conditions":"Healthy","enrollment":80},{"nctId":"NCT00835042","phase":"PHASE1","title":"Moexipril HCL/Hydrochlorothiazide 15/25 mg Tablets Under Fasting Conditions","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2003-10","conditions":"Healthy","enrollment":60},{"nctId":"NCT00834067","phase":"PHASE1","title":"Moexipril HCl/Hydrochlorothiazide 15/25 mg Tablets Under Non-Fasting Conditions","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2003-10","conditions":"Healthy","enrollment":60},{"nctId":"NCT00398541","phase":"PHASE3","title":"Evaluation of the Antihypertensive Effect of Hyzaar(R) and Cognitive Function of Hypertensive Patients (0954A-322)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-03-01","conditions":"Hypertension","enrollment":41},{"nctId":"NCT00307060","phase":"PHASE3","title":"MK0954A-264 Filter Study (0954A-264)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2004-12-01","conditions":"Mild to Severe Hypertension","enrollment":274},{"nctId":"NCT00480805","phase":"PHASE3","title":"HYZAAR vs. Ramipril for Diabetes (0954A-245)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2001-08-08","conditions":"Type 2 Diabetes Mellitus, Hypertension","enrollment":312},{"nctId":"NCT00400218","phase":"PHASE3","title":"Evaluate the Safety and Anti-Hypertensive Efficacy of Hyzaar(R) In Patients With Mild To Moderate Essential Hypertension (0954A-323)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-09-01","conditions":"Hypertension","enrollment":62},{"nctId":"NCT00157963","phase":"PHASE4","title":"Hydrochlorothiazide (+) Losartan Potassium vs. Amlodipine Comparative Study (0954A-314)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-02-05","conditions":"Essential Hypertension","enrollment":174},{"nctId":"NCT00449111","phase":"PHASE3","title":"An Open Label Study to Assess the Efficacy, Safety and Tolerability of COZAAR Plus (Losartan Potassium 50mg/Hydrochlorothiazide 12.5mg) Possibly Titrated up to COZAAR Plus-F (Losartan Potassium 100mg/Hydrochlorothiazide 25mg) in Patients With Essential Hypertension (0954A-325)","status":"TERMINATED","sponsor":"Organon and Co","startDate":"2006-03-13","conditions":"Hypertension","enrollment":11},{"nctId":"NCT00140959","phase":"PHASE4","title":"Losartan and HCTZ and Amlodipine vs Atenolol and Amlodipine (0954A-309)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2003-02-01","conditions":"Hypertension","enrollment":120},{"nctId":"NCT05582837","phase":"PHASE4","title":"Treatment of Meniere's Disease With Migraine Medications","status":"RECRUITING","sponsor":"University of California, Irvine","startDate":"2022-08-01","conditions":"Ménière","enrollment":100},{"nctId":"NCT03109795","phase":"PHASE4","title":"Anxiety-mediated Impairments in Large Elastic Artery Function and the Autonomic Nervous System","status":"TERMINATED","sponsor":"University of Iowa","startDate":"2017-04-10","conditions":"Anxiety, Hypertension","enrollment":35},{"nctId":"NCT06491940","phase":"NA","title":"Comparison of the Role of Losartan Alone vs Hydrochlorothiazide Plus Losartan","status":"NOT_YET_RECRUITING","sponsor":"RESnTEC, Institute of Research","startDate":"2024-08-01","conditions":"Proteinuria","enrollment":234},{"nctId":"NCT00447603","phase":"PHASE3","title":"A Study of Losartan Compared to Losartan/HCTZ in Pediatric Patients With Hypertension (0954A-327)","status":"TERMINATED","sponsor":"Organon and Co","startDate":"2007-05-24","conditions":"Hypertension","enrollment":40},{"nctId":"NCT05917275","phase":"PHASE4","title":"Multi-Omics to Predict the Blood Pressure Response to Antihypertensives","status":"RECRUITING","sponsor":"Radboud University Medical Center","startDate":"2024-04-04","conditions":"Primary Hypertension","enrollment":96},{"nctId":"NCT06366386","phase":"","title":"Integrating Hypertension Management in DSD for HIV","status":"NOT_YET_RECRUITING","sponsor":"Infectious Diseases Research Collaboration, Uganda","startDate":"2024-06-15","conditions":"Hypertension, HIV","enrollment":1100},{"nctId":"NCT00496834","phase":"PHASE4","title":"LAAS (Losartan Anti-Atherosclerosis Study)(0954-330)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2008-02-01","conditions":"Hypertension","enrollment":201},{"nctId":"NCT02185417","phase":"PHASE3","title":"Diuretic Comparison Project","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2016-06-15","conditions":"Hypertension","enrollment":20723},{"nctId":"NCT01431508","phase":"PHASE4","title":"A Study of Safety and Efficacy in MK-0954A Combination in Participants With Hypertension (MK-0954A-373 AM3)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2007-08-01","conditions":"Hypertension","enrollment":15},{"nctId":"NCT01307046","phase":"PHASE3","title":"MK-0954A in Japanese Patients With Essential Hypertension Not Adequately Controlled With Losartan (MK-0954A-352)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2011-03-29","conditions":"Hypertension","enrollment":336},{"nctId":"NCT01307033","phase":"PHASE3","title":"A Long-term Study of the Safety of MK-0954A in Patients With Essential Hypertension (MK-0954A-351)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2011-03-29","conditions":"Hypertension","enrollment":278},{"nctId":"NCT00546052","phase":"PHASE3","title":"A 52 Week Study to Evaluate the Effects of Losartan With or Without HCTZ on Plasma Glucose, Metabolic Parameters, Blood Pressure in Hypertensive Patients With Metabolic Syndrome (0954A-331)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-09-01","conditions":"Hypertension, Metabolic Disorder","enrollment":1738},{"nctId":"NCT00546754","phase":"PHASE3","title":"BP-EASE -Effectiveness of Losartan 50 mg/Hydrochlorothiazide (HCTZ) 12.5 mg Versus Valsartan 80 mg/HCTZ 12.5 mg Titrated as Needed in Patients With Essential Hypertension Not Controlled on Monotherapy (0954A-333)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2007-05-01","conditions":"Hypertension","enrollment":808},{"nctId":"NCT00739674","phase":"PHASE3","title":"SAALT: Subtracting Salt and Adding Losartan Trial (0954A-335)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2008-02-01","conditions":"Hypertension","enrollment":992},{"nctId":"NCT06395194","phase":"PHASE3","title":"Effects of Valsartan vs Amlodipine and Low BP on Kidney Outcomes in Essential Hypertension","status":"COMPLETED","sponsor":"Oslo University Hospital","startDate":"1997-09-27","conditions":"Essential Hypertension","enrollment":15313},{"nctId":"NCT00006294","phase":"","title":"Genetics of Hypertension Associated Treatments (GenHAT)","status":"COMPLETED","sponsor":"Donna Arnett, 257-5678","startDate":"1999-09","conditions":"Cardiovascular Diseases, Heart Diseases, Hypertension","enrollment":37939},{"nctId":"NCT00649688","phase":"PHASE1","title":"Fasting Study of Metoprolol Tartrate/Hydrochlorothiazide Tablets 100/50 mg and Lopressor HCT® Tablets 100/50 mg","status":"COMPLETED","sponsor":"Mylan Pharmaceuticals Inc","startDate":"2003-01","conditions":"Healthy","enrollment":32},{"nctId":"NCT00649441","phase":"PHASE1","title":"Fasting Study of Quinapril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg to Accuretic™ Tablets 20 mg/25 mg","status":"COMPLETED","sponsor":"Mylan Pharmaceuticals Inc","startDate":"2003-08","conditions":"Healthy","enrollment":60},{"nctId":"NCT00649597","phase":"PHASE1","title":"Fasting Study of Benazepril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg to Lotensin HCT® Tablets 20 mg/25 mg","status":"COMPLETED","sponsor":"Mylan Pharmaceuticals Inc","startDate":"2002-11","conditions":"Healthy","enrollment":56},{"nctId":"NCT00649233","phase":"PHASE1","title":"Food Study of Metoprolol Tartrate/Hydrochlorothiazide Tablets 100/50 mg to Lopressor HCT® Tablets 100/50 mg","status":"COMPLETED","sponsor":"Mylan Pharmaceuticals Inc","startDate":"2003-01","conditions":"Healthy","enrollment":32},{"nctId":"NCT00649038","phase":"PHASE1","title":"Fed Study of Benazepril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg to Lotensin HCT® Tablets 20 mg/25 mg","status":"COMPLETED","sponsor":"Mylan Pharmaceuticals Inc","startDate":"2002-12","conditions":"Healthy","enrollment":24},{"nctId":"NCT00649324","phase":"EARLY_PHASE1","title":"Fasting Study of Hydrochlorothiazide Tablets 50 mg to Hydrochlorothiazide Tablets 50 mg","status":"COMPLETED","sponsor":"Mylan Pharmaceuticals Inc","startDate":"2005-10","conditions":"Healthy","enrollment":40},{"nctId":"NCT00648011","phase":"PHASE1","title":"Food Study of Quinapril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg to Accuretic™ Tablets 20 mg/25 mg","status":"COMPLETED","sponsor":"Mylan Pharmaceuticals Inc","startDate":"2003-08","conditions":"Healthy","enrollment":44},{"nctId":"NCT01019590","phase":"PHASE1","title":"Fed Study of Olmesartan Medoxomil and Hydrochlorothiazide Tablets 40 mg/25 mg and Benicar HCT® Tablets 40 mg/25 mg","status":"COMPLETED","sponsor":"Mylan Pharmaceuticals Inc","startDate":"2006-11","conditions":"Healthy","enrollment":36},{"nctId":"NCT01020214","phase":"PHASE1","title":"Fasting Study of Olmesartan Medoxomil and Hydrochlorothiazide Tablets 40 mg/25 mg and Benicar HCT® Tablets 40 mg/25 mg","status":"COMPLETED","sponsor":"Mylan Pharmaceuticals Inc","startDate":"2006-11","conditions":"Healthy","enrollment":36},{"nctId":"NCT03179163","phase":"PHASE1, PHASE2","title":"Peripheral Vascular Effects of Sulfhydryl-containing Antihypertensive Pharmacotherapy on Microvessels in Humans","status":"TERMINATED","sponsor":"Penn State University","startDate":"2016-07-20","conditions":"Hypertension,Essential","enrollment":10},{"nctId":"NCT03057431","phase":"PHASE3","title":"Hydrochlorothiazide for Kidney Stone Recurrence Prevention","status":"COMPLETED","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2017-03-09","conditions":"Nephrolithiasis","enrollment":416},{"nctId":"NCT05685277","phase":"PHASE1","title":"Bioequivalence Study of Two Formulations of Tablets Ramipril/Hydrochlorothiazide 10 mg/25 mg in Healthy Volunteers Under Fasting Conditions","status":"COMPLETED","sponsor":"Pharmtechnology LLC","startDate":"2022-12-28","conditions":"Bioequivalence","enrollment":50},{"nctId":"NCT02262780","phase":"PHASE1","title":"Safety, Tolerability and Pharmacokinetics of Single Rising and Multiple Oral Doses of Telmisartan / Hydrochlorothiazide (HCTZ) in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2003-12-01","conditions":"Healthy","enrollment":20},{"nctId":"NCT03298802","phase":"PHASE3","title":"Postpartum Management of Hypertension in Pregnancy With Hydrochlorothiazide","status":"UNKNOWN","sponsor":"The University of Texas Medical Branch, Galveston","startDate":"2017-11-21","conditions":"Pre-Eclampsia, Gestational Hypertension, Superimposed Pre-Eclampsia","enrollment":612},{"nctId":"NCT00170950","phase":"PHASE3","title":"Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension","status":"TERMINATED","sponsor":"Novartis","startDate":"2003-10","conditions":"Hypertension","enrollment":11506},{"nctId":"NCT05443932","phase":"PHASE4","title":"Dapagliflozin and Hydrochlorothiazide in Recurring Kidney Stone Patients","status":"UNKNOWN","sponsor":"Medical University of Vienna","startDate":"2024-03-04","conditions":"Urolithiasis, Hyperoxaluria","enrollment":32},{"nctId":"NCT00171015","phase":"PHASE3","title":"VALORY Study of Valsartan/Hydrochlorizide for Patients Who do Not Respond Adequately to Olmesartan Medoxomil","status":"COMPLETED","sponsor":"Novartis","startDate":"2004-12","conditions":"Hypertension","enrollment":212},{"nctId":"NCT06083116","phase":"PHASE1","title":"Drug-Drug Interaction Study Between Henagliflozin Proline and Hydrochlorothiazide","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2019-08-28","conditions":"Diabetes in Adults","enrollment":12},{"nctId":"NCT00171782","phase":"PHASE4","title":"Hypertension and Cardiovascular Risk Factors","status":"COMPLETED","sponsor":"Novartis","startDate":"2004-02","conditions":"HYPERTENSION","enrollment":76},{"nctId":"NCT01326676","phase":"PHASE3","title":"Polypill Effects on Sub Clinical Atherosclerosis (PESCA) Trial","status":"WITHDRAWN","sponsor":"Imperial College London","startDate":"2011-02","conditions":"Cardiovascular Disease","enrollment":""},{"nctId":"NCT02046395","phase":"PHASE4","title":"Effect of Renin-angiotensin-system Blockade on Urinary Free Light Chains in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Tulane University School of Medicine","startDate":"2012-01","conditions":"Type 2 Diabetes, Hypertension","enrollment":28},{"nctId":"NCT00656331","phase":"NA","title":"The Pleiotropic Effects of Atorvastatin When Combined With Common Antihypertenisve Medications.","status":"WITHDRAWN","sponsor":"University of New Mexico","startDate":"2005-08","conditions":"Hypertension","enrollment":""},{"nctId":"NCT00751829","phase":"PHASE3","title":"Isolated Systolic Hypertension in the Elderly and Very Elderly","status":"COMPLETED","sponsor":"Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company","startDate":"2003-07","conditions":"Isolated Systolic Hypertension","enrollment":417},{"nctId":"NCT02711670","phase":"NA","title":"Night Time Use of Thiazide Diuretics for Improved Reduction in Stone Risk in Stone Formers With Elevated Urine Calcium","status":"COMPLETED","sponsor":"VA New York Harbor Healthcare System","startDate":"2014-02","conditions":"Kidney Stones","enrollment":10},{"nctId":"NCT01983462","phase":"PHASE2","title":"Vascular Dysfunction in Human Obesity Hypertension","status":"TERMINATED","sponsor":"Gary L. Pierce","startDate":"2013-10","conditions":"Obesity, Prehypertension, Hypertension","enrollment":33},{"nctId":"NCT03682692","phase":"PHASE4","title":"ACEI/CCB Versus ACEI/DIU Combination Antihypertensive Therapy in Chinese Hypertensive Patients (ACvAD)","status":"COMPLETED","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2018-06-01","conditions":"Hypertension","enrollment":560},{"nctId":"NCT04964050","phase":"PHASE1","title":"A Bioequivalence Study Between Capozide Versus ACE-Hemmer-ratiopharm in Healthy Adult Participants Under Fasting Conditions","status":"WITHDRAWN","sponsor":"GlaxoSmithKline","startDate":"2022-04-21","conditions":"Healthy Volunteers","enrollment":""},{"nctId":"NCT03261375","phase":"NA","title":"To Evaluate Safety and Efficacy of a Radiofrequency Renal Denervation System in Treatment of Essential Hypertension","status":"COMPLETED","sponsor":"Shanghai Golden Leaf MedTec Co. Ltd","startDate":"2021-01-19","conditions":"Hypertension","enrollment":205},{"nctId":"NCT01692717","phase":"PHASE1","title":"Clinical Assessment Of Association Pharmacokinetics Atorvastatin + Losartana + Hydrochlorothiazide","status":"COMPLETED","sponsor":"Azidus Brasil","startDate":"2013-02-28","conditions":"Healthy Subjects","enrollment":90},{"nctId":"NCT01647932","phase":"PHASE3","title":"Safety and Efficacy of the Combination of Loop With Thiazide-type Diuretics in Patients With Decompensated Heart Failure","status":"COMPLETED","sponsor":"Spanish Society of Internal Medicine","startDate":"2014-10","conditions":"Heart Failure","enrollment":232},{"nctId":"NCT01313702","phase":"PHASE3","title":"Single Pill to Avert Cardiovascular Events","status":"WITHDRAWN","sponsor":"Hospital do Coracao","startDate":"2012-10","conditions":"Cardiovascular Disease","enrollment":""},{"nctId":"NCT05545059","phase":"PHASE3","title":"Effects and Safety of Sacubitril/Valsartan on Refractory Hypertension","status":"UNKNOWN","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2022-09-24","conditions":"Resistant Hypertension","enrollment":138},{"nctId":"NCT03461003","phase":"PHASE4","title":"N-of-1 Trials In Children With Hypertension","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2018-04-02","conditions":"Pediatric Hypertension","enrollment":49},{"nctId":"NCT01620788","phase":"PHASE3","title":"Comparison of Losartan Associated With Indapamide Versus Hyzaar® in the Hypertension Treatment","status":"SUSPENDED","sponsor":"EMS","startDate":"2019-11-27","conditions":"Hypertension","enrollment":636},{"nctId":"NCT03205137","phase":"","title":"Comparison of the Medication Adherence of Patients Treated With Telmisartan/Hydrochlorothiazide or Telmisartan/Amlodipine Fixed Dose Combination (FDC) Versus Double-pill Combination Therapy in Real-world Japanese Therapeutic Practice","status":"WITHDRAWN","sponsor":"Boehringer Ingelheim","startDate":"2022-06-01","conditions":"Hypertension","enrollment":""}],"_emaApprovals":[],"_faersSignals":[{"count":7,"reaction":"DRUG INEFFECTIVE"},{"count":5,"reaction":"ACUTE KIDNEY INJURY"},{"count":4,"reaction":"CHRONIC KIDNEY DISEASE"},{"count":4,"reaction":"MALAISE"},{"count":4,"reaction":"PAIN"},{"count":3,"reaction":"BALANCE DISORDER"},{"count":3,"reaction":"CONDITION AGGRAVATED"},{"count":3,"reaction":"DIZZINESS"},{"count":3,"reaction":"FALL"},{"count":3,"reaction":"NAUSEA"}],"_approvalHistory":[],"publicationCount":1119,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["MICROZIDE™","HCTZ","Hydrochlorothiazide","Apo-Hydro","Aquazide H"],"phase":"marketed","status":"active","brandName":"Hydrochlorothiazide (HCTZ)","genericName":"Hydrochlorothiazide (HCTZ)","companyName":"Novartis","companyId":"novartis","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Hydrochlorothiazide inhibits sodium and chloride reabsorption in the distal convoluted tubule of the kidney, promoting water and electrolyte excretion to reduce blood volume and blood pressure. Used for Hypertension, Edema associated with congestive heart failure, Edema associated with renal disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}